SCHEMBL14697174

SCHEMBL14697174

O=C(CSc1nc2ccccc2c(=O)n1-c1ccc(F)c(Cl)c1)Nc1ccc2c(c1)CCC2

nearest known ligand 0.81

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.77
▸ KMT2A Q03164 6/20 0.77
▸ KDM4E B2RXH2 1/20 0.65
▸ SMN1; SMN2 Q16637 2/20 0.60
▸ RECQL P46063 1/20 0.58
▸ HTT P42858 1/20 0.56
▸ RAF1 P04049 1/20 0.54
▸ BRAF P15056 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ USP2 O75604 2/20 0.52
▸ MEN1 O00255 5/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14697159 0.93 MAPT (0.72) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14697084 0.93 MAPT (0.80) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14697221 0.92 MAPT (0.65) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14697381 0.91 MAPT (0.77) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14697132 0.90 MAPT (0.81) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14698699 0.90 MAPT (0.62) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14697311 0.90 MAPT (0.75) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14697166 0.89 MAPT (0.69) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14697274 0.89 MAPT (0.69) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14697267 0.88 MAPT (0.81) MAPTKMT2ASMN1; SMN2RECQLHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE 2017-05-25 — — US claimed
US-9598402-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections SOUTHERN RESEARCH INSTITUTE (US) 2017-03-21 — — US claimed
EP-2744787-B1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RES INST (US) 2016-11-02 — — EP claimed
US-20140256753-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2014-09-11 — — US claimed
EP-2744787-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS Southern Research Institute (US) 2014-06-25 — — EP claimed
WO-2013025508-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE (US) 2013-02-21 — — WO claimed
US-10611733-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2020-04-07 — — US disclosed
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE 2017-05-25 — — US disclosed
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE 2017-05-25 — — US disclosed
US-9598402-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections SOUTHERN RESEARCH INSTITUTE (US) 2017-03-21 — — US disclosed
US-9598402-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections SOUTHERN RESEARCH INSTITUTE (US) 2017-03-21 — — US disclosed
EP-2744787-B1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RES INST (US) 2016-11-02 — — EP disclosed
US-20140256753-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2014-09-11 — — US disclosed
US-20140256753-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2014-09-11 — — US disclosed
EP-2744787-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS Southern Research Institute (US) 2014-06-25 — — EP disclosed
WO-2013025508-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE (US) 2013-02-21 — — WO disclosed
WO-2013025508-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE (US) 2013-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256753-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS HAVCR2, EIF2AK2, GLS2 MAPT 1316/4885KMT2A 3419/4885KDM4E 3772/4885
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS ZC3HAV1, EIF2AK2, GTF3C3 MAPT 1974/4885KMT2A 3065/4885KDM4E 3408/4885
US-10611733-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections ZC3HAV1, EIF2AK2, GTF3C3 MAPT 1974/4885KMT2A 3065/4885KDM4E 3408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback